Background: The PD-L1 assessment is mandatory for the selection of patients affected by advanced non-small-cell lung cancer (NSCLC) who can benefit from the PD-1/PD-L1 checkpoint inhibitors therapy. Previous studies tested PD-L1 on cytological smears to evaluate this sample as an alternative to formalin-fixed paraffin-embedded (FFPE) ones, but several critical issues needed to be clarified.Aim: We evaluated the cyto-histological agreement (CHA) and the PD-L1 interobserver agreement (IrOA) among three different pathologists (Path1, Path2, Path3) on 160 paired cytological smears and histological samples of advanced NSCLC.Results: With the cut-off of < 50%/> 50%, CHA resulted good for Path1 (Cohen's k: 0.702) and Path3 (Cohen's k: 0.731), moderate for Path2 (Cohen's k: 0.576) adopting the same cut-off, the IrOA was moderate (ICC 0.72 [95% CI: 0.63-0.78]) for smears and good for histological samples (ICC 0.85 [95% CI: 0.80-0.85]).Conclusion: With a cut-off system of < 50%/> 50%, PD-L1 assessment shows moderate to good CHA and exhibited moderate IrOA on smears and good IrOA on FFPE. As result, PD-L1 assessment should be improved on cytological smears as well as could be a suitable alternative for patients without FFPE samples and not eligible for pembrolizumab, adopting a cut-off of < 50%/> 50%; presumably, an appropriate pathologist training could further improve the reproducibility.

Ambrosi, F., Giunchi, F., Capizzi, E., Cancellieri, A., Trisolini, R., Ardizzoni, A., Fiorentino, M., Ricci, C., Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples, <<PATHOLOGY RESEARCH AND PRACTICE>>, 2022; 233 (2022): 153893-153896. [doi:10.1016/j.prp.2022.153893] [https://hdl.handle.net/10807/222157]

Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples

Cancellieri, Alessandra;Trisolini, Rocco;
2022

Abstract

Background: The PD-L1 assessment is mandatory for the selection of patients affected by advanced non-small-cell lung cancer (NSCLC) who can benefit from the PD-1/PD-L1 checkpoint inhibitors therapy. Previous studies tested PD-L1 on cytological smears to evaluate this sample as an alternative to formalin-fixed paraffin-embedded (FFPE) ones, but several critical issues needed to be clarified.Aim: We evaluated the cyto-histological agreement (CHA) and the PD-L1 interobserver agreement (IrOA) among three different pathologists (Path1, Path2, Path3) on 160 paired cytological smears and histological samples of advanced NSCLC.Results: With the cut-off of < 50%/> 50%, CHA resulted good for Path1 (Cohen's k: 0.702) and Path3 (Cohen's k: 0.731), moderate for Path2 (Cohen's k: 0.576) adopting the same cut-off, the IrOA was moderate (ICC 0.72 [95% CI: 0.63-0.78]) for smears and good for histological samples (ICC 0.85 [95% CI: 0.80-0.85]).Conclusion: With a cut-off system of < 50%/> 50%, PD-L1 assessment shows moderate to good CHA and exhibited moderate IrOA on smears and good IrOA on FFPE. As result, PD-L1 assessment should be improved on cytological smears as well as could be a suitable alternative for patients without FFPE samples and not eligible for pembrolizumab, adopting a cut-off of < 50%/> 50%; presumably, an appropriate pathologist training could further improve the reproducibility.
Inglese
Ambrosi, F., Giunchi, F., Capizzi, E., Cancellieri, A., Trisolini, R., Ardizzoni, A., Fiorentino, M., Ricci, C., Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples, <<PATHOLOGY RESEARCH AND PRACTICE>>, 2022; 233 (2022): 153893-153896. [doi:10.1016/j.prp.2022.153893] [https://hdl.handle.net/10807/222157]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/222157
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact